Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) is a clinical-stage biopharmaceutical company concentrated on neuroscience, developing therapies for conditions including schizophrenia, Parkinson's disease, epilepsy, and addiction. The company entered the public markets in 2020 through a business combination with ARYA Sciences Acquisition Corp II, a blank-check vehicle sponsored by Perceptive Advisors. Originally formed as a spinout from Pfizer in collaboration with Bain Capital in 2018, Cerevel has built a portfolio of selective receptor-targeting compounds targeting the central nervous system. The company filed a Form 8-K with the SEC on June 8, 2023, maintaining its active reporting status as a publicly traded biopharmaceutical issuer. Sign up at SpacDesk for full SPAC transaction data, filing history, and real-time coverage on Cerevel and hundreds of other de-SPAC companies.